This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In most cancers, the tumour evolves by acquiring mutations that confer growth advantages or resistance to therapies. Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. This allows the cancer to evolve and develop resistance to the therapy.
Compared to traditional antibody therapies, how does the precision binding approach in your antibody design impact the therapeutic window and dosing regimen in preclinical models? Our approach represents a paradigm shift. Traditional drug discovery is based on the premise that target proteins have biological functions.
One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases. As a direct consequence, in silico methods in human clinical trials are emerging as an important new paradigm in the development of medical therapies – particularly useful for rare diseases.
At the Broad, he directs the Cancer Genome Computational Analysis Group , and he is a professor of pathology at Harvard Medical School and director of bioinformatics at Massachusetts General Hospital. She has developed innovative approaches to viral diagnostics and novel systems biology approaches to gene regulation and gene therapy.
Joneckis said that CBER has “some limited uses that we have seen in external submissions, mostly in the bioinformatics area,” but not as many as CDER. Marks also offered thoughts on the “critical juncture” for gene therapies. With 15 gene therapies now approved in the U.S., With 15 gene therapies now approved in the U.S.,
Immunotherapy has become a cornerstone of cancer therapy and significantly improved patient outcomes Immunotherapy has become a cornerstone of cancer therapy and significantly improved patient outcomes The tumour regression at the metastatic site (abscopal effect) in the 4T1 tumour model is driven by CD8+ killer T cells.
This paper paves the way for off-the-shelf cell therapies that don’t require immunosuppressive drugs. link ) Administering multiple doses of lentiviral vectors (used for gene therapy) into mouse lungs is better for long-term gene expression than a single dose. Gene Therapy. Bioinformatics. Bioinformatics.
This paper paves the way for off-the-shelf cell therapies that don’t require immunosuppressive drugs. link ) Administering multiple doses of lentiviral vectors (used for gene therapy) into mouse lungs is better for long-term gene expression than a single dose. Gene Therapy. Bioinformatics. Bioinformatics.
Compact gene editors , called enOsCas12f1 and enRhCas12f1, are smaller than many existing Cas proteins and can thus be more easily delivered in a single virus for gene therapies. BMC Bioinformatics. Read Development of a translatable gene augmentation therapy for CNGB1-Retinitis Pigmentosa. Molecular Therapy. Occelli L.M.
When our backs were against the wall, the biotech/biopharma community came together to create not one, but two vaccines currently approved for emergency use in the U.S. The last year, I think, is a very exciting year for cell therapy against cancer. This has earned the industry a lot of respect. It’s because the tumor metastasized.
Craig Venter Higher Animals: Vaccines, Synthetic Biology, and the Future of Life , by Michael Specter What’s Your Bio Strategy? , iGEM | Engineering Biology Research Consortium | ValleyDAO | Build-A-Cell | * DNA Deviants | * Bits in Bio | SBOL Community | Biodesign Challenge Thanks for reading. .
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content